The physiologic balance between PTH action and established Wnt-pathway inhibitors, with their altered interplay in the presence of hyperparathyroidism, may explain the skeletal involvement in PHPT, which can range from normal bone to severe osteoporosis. This evidence concerns the gene PTH and hyperparathyroidism.